Luzhe Sun received his Ph.D. degree in physiology from Rutgers, The State University of New Jersey and UMDNJ, Robert Wood Johnson Medical School in 1990 and obtained his postdoctoral training in Baylor College of Medicine in the USA. He became an independent researcher in 1995 as Tenure-Track Assistant Professor of Pharmacology in the University of Kentucky School of Medicine and serves currently as a Professor of cellular and structural biology, Dielmann Endowed Chair in Oncology, and an Associate Director for Translational Research at the Cancer Treatment and Research Center in the University of Texas Health Science Center. He also serves as an Inaugural Leader of the Cell and Molecular Biology Track of the Integrated Multidisciplinary Graduate Program at his institution. His research is focused on investigating molecular mechanisms of tumorigenesis and metastasis, and novel experimental therapeutics in various models of carcinomas in the past two decades. He participated in the discovery of the tumor suppressor role of TGFß type II receptor in hereditary nonpolyposis colorectal cancer and pioneered the use of a soluble TGFß type III receptor and the engineer of a soluble chimeric TGFß receptor for the inhibition of cancer growth, angiogenesis, and metastasis in various preclinical models of human cancers. Currently, his laboratory is investigating various cellular signaling pathways, particularly the hormonal signaling and TGFß signaling pathways, in driving cancer development, growth, and metastasis, and the effect of aging on the function, genomic integrity, and susceptibility to transformation of mammary stem cells. His research has been supported with multimillion dollar funding from National Institutes of Health, Department of Defense, the University of Texas Health Science Center, and other private foundations.
Biography Updated on 10 June 2012